Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies

Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting

(2010) Marco Vergine et al.   HISTOPATHOLOGY

Optimizing the Delivery of Targeted Research: An Opportunity for Comparative Effectiveness Research

(2010) Kathleen I. Pritchard   JOURNAL OF CLINICAL ONCOLOGY

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

(2010) John MS Bartlett et al.   LANCET ONCOLOGY

Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge

(2010) A F Munro et al.   ONCOGENE

Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more?

(2009) Catherine Oakman et al.   BREAST

The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients

(2009) Catherine Oakman et al.   CANCER TREATMENT REVIEWS

Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy inHER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013

(2009) Lyndsay N. Harris et al.   JOURNAL OF CLINICAL ONCOLOGY

AreHER2andTOP2AUseful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?

(2009) Kathleen I. Pritchard   JOURNAL OF CLINICAL ONCOLOGY

Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

(2009) F. P. O'Malley et al.   JNCI-Journal of the National Cancer Institute

HER-2/neu Assessment in Breast Cancer Using the Original FDA and New ASCO/CAP Guideline Recommendations

(2008) Matteo Brunelli et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy

(2008) Kathleen I. Pritchard et al.   JOURNAL OF CLINICAL ONCOLOGY